Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Structure-Based Design of A-1293102, a Potent and Selective BCL-XL Inhibitor.
Tao ZF, Wang X, Chen J, Ingram JP, Jin S, Judge RA, Kovar PJ, Park C, Sun C, Wakefield BD, Zhou L, Zhang H, Elmore SW, Phillips DC, Judd AS, Leverson JD, Souers AJ. Tao ZF, et al. Among authors: wakefield bd. ACS Med Chem Lett. 2021 May 12;12(6):1011-1016. doi: 10.1021/acsmedchemlett.1c00162. eCollection 2021 Jun 10. ACS Med Chem Lett. 2021. PMID: 34141086 Free PMC article.
Scaffold oriented synthesis. Part 4: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing heterocycle forming and multicomponent reactions.
Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW. Akritopoulou-Zanze I, et al. Among authors: wakefield bd. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1480-3. doi: 10.1016/j.bmcl.2011.01.001. Epub 2011 Jan 11. Bioorg Med Chem Lett. 2011. PMID: 21288717
Scaffold oriented synthesis. Part 3: design, synthesis and biological evaluation of novel 5-substituted indazoles as potent and selective kinase inhibitors employing [2+3] cycloadditions.
Akritopoulou-Zanze I, Wakefield BD, Gasiecki A, Kalvin D, Johnson EF, Kovar P, Djuric SW. Akritopoulou-Zanze I, et al. Among authors: wakefield bd. Bioorg Med Chem Lett. 2011 Mar 1;21(5):1476-9. doi: 10.1016/j.bmcl.2011.01.007. Epub 2011 Jan 11. Bioorg Med Chem Lett. 2011. PMID: 21282054
cis-4-(Piperazin-1-yl)-5,6,7a,8,9,10,11,11a-octahydrobenzofuro[2,3-h]quinazolin-2-amine (A-987306), a new histamine H4R antagonist that blocks pain responses against carrageenan-induced hyperalgesia.
Liu H, Altenbach RJ, Carr TL, Chandran P, Hsieh GC, Lewis LG, Manelli AM, Milicic I, Marsh KC, Miller TR, Strakhova MI, Vortherms TA, Wakefield BD, Wetter JM, Witte DG, Honore P, Esbenshade TA, Brioni JD, Cowart MD. Liu H, et al. Among authors: wakefield bd. J Med Chem. 2008 Nov 27;51(22):7094-8. doi: 10.1021/jm8007618. J Med Chem. 2008. PMID: 18983139
Preparation of novel anthranilic acids as antibacterial agents: extensive evaluation of structural and physical properties on antibacterial activity and human serum albumin affinity.
Thorarensen A, Li J, Wakefield BD, Romero DL, Marotti KR, Sweeney MT, Zurenko GE, Sarver RW. Thorarensen A, et al. Among authors: wakefield bd. Bioorg Med Chem Lett. 2007 Jun 1;17(11):3113-6. doi: 10.1016/j.bmcl.2007.03.036. Epub 2007 Mar 15. Bioorg Med Chem Lett. 2007. PMID: 17400450
Bacterial translation inhibitors, 1-acylindazol-3-ols as anthranilic acid mimics.
Stiff C, Graber DR, Thorarensen A, Wakefield BD, Marotti KR, Melchior EP, Sweeney MT, Han F, Rohrer DC, Zurenko GE, Romero DL. Stiff C, et al. Among authors: wakefield bd. Bioorg Med Chem Lett. 2008 Dec 1;18(23):6293-7. doi: 10.1016/j.bmcl.2007.08.041. Epub 2007 Aug 25. Bioorg Med Chem Lett. 2008. PMID: 18951783
12 results